Amycretin, the Danish drugmaker's next-generation obesity drug, has a dual-mode action. Like its popular weight-loss drug Wegovy, amycretin not only mimics the gut hormone GLP-1, but also the effect of a hunger-suppressing pancreatic hormone called amylin. Read more: https://pharma.economictimes.indiatimes.com/news/pharma-industry/novo-nordisk-to-initiate-late-stage-trials-for-obesity-drug-amycretin-in-2026/121815033